Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Benign MS Expresses Itself
BIIB033
European Commission Approves Alemtuzumab (Lemtrada)
Rituximab
Commentary: Outcome measures were flawed.
Papers: 6 May 2016 - 13 May 2016
Old Drug Performs New Trick
Papers: 26 Apr 2016 - 3 May 2016
Estriol
What’s the Role of Myelin Oligodendrocyte Glycoprotein in NMO?
Ozanimod
Fingolimod
Webinars Coming...
Papers: 18 Apr 2016 - 25 Apr 2016
Altered Immunity, Crippled Neurons
Why have annualized relapse rates in RRMS trials decreased?
Low Testosterone Linked to Disability in Men With MS
Stem Cell Transplants Risky But Effective
Biomarkers in MS
Cheap Vaccine Slows MS Progression
Daclizumab
Significant Reduced Loss of Brain Volume in Multiple Sclerosis Patients Treated with COPAXONE(R)
Genetic Associations
Siponimod
Discriminatory Disease
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »